29.3 C
Vientiane
Saturday, June 21, 2025
spot_img
Home Blog Page 3027

Greenliant Launches High Capacity 1TB microSD ArmourDrive(TM) Industrial Memory Cards

Offering Reliability, Portability and Durability at Wide Temperature Ranges

 

BEIJING, CHINA and SANTA CLARA, US – EQS Newswire – 1 March 2021 – Greenliant has expanded its ArmourDrive™ industrial memory card portfolio with the high reliability, high capacity microSD QX Series, available from 256GB to 1TB, and operating at wide temperatures (-25 to +85 degrees Celsius). See microSD ArmourDrive product information at http://bit.ly/SD-microSD.


High Capacity microSD ArmourDrive™ Industrial Memory Cards


Industrial microSD memory cards have become a popular storage medium for a broad range of applications, including dashcams and bodycams, data loggers, routers and switches, medical equipment and IIoT devices. Built with high quality, advanced 4-bit-per-cell (QLC) 3D NAND flash memory, microSD ArmourDrive QX Series products provide video, security, networking and industrial customers with cost effective, reliable and rugged removable data storage. UHS Speed Class 10 and SD Specification 6.10 compliant, microSD ArmourDrive QX Series cards reach up to 100/37 MB/s sequential read/write performance and are ideal for video recording at high definition resolution.

Benefits of 93 QX Series microSD ArmourDrive memory cards include:

  • Wide Temperature: Operates between -25 and +85 degrees Celsius
  • Large Capacity: 256 GB, 512 GB, 1 TB
  • High Performance: Supports UHS I-104 ultra high bus speed mode
  • Energy Efficient: Active power consumption less than 400 mA; standby mode less than 1 mA
  • Rugged: Resistant to shock (1500G), vibration (20G) and water (IPX7 rating)
  • Reliable: Achieves more than 2 million hours for Mean Time Between Failures (MTBF)
  • SMART Support: Monitors remaining useful product life


Availability

Greenliant will start sampling microSD ArmourDrive QX Series industrial memory cards at the end of March and expects to start production shipments in April of this year. For more information about 93 QX Series products, contact a Greenliant channel partner, https://www.greenliant.com/sales.

About Greenliant

By leveraging more than 30 years of solid state storage design expertise, Greenliant is dedicated to developing durable, reliable and secure storage solutions for embedded systems and enterprise datacenters. The company is headquartered in Silicon Valley with product development centers in Santa Clara, Beijing, Shanghai, Xiamen and Hsinchu. https://www.greenliant.com

Greenliant, the Greenliant logo and ArmourDrive are trademarks of Greenliant. All other trademarks used herein are the property of their respective owners.


How the documenta invented the “Zero Hour” in art after 1945

“documenta. Politics and Art” from 18 June 2021 to 9 January 2022

 

BERLIN, GERMANY – Newsaktuell – 1 March 2021 – The documenta owes its rise to the most successful German art exhibition not least to its political dimension: its disassociation from National Socialism and the bloc building of the Cold War. It was informed on the one hand by the supposed attempt to distance itself radically from Nazi cultural politics while at the same time refusing to deal openly with the Nazi past. On the other hand, its politically motivated orientation on the West included a decided aloofness toward and denigration of the socialist art of the “Eastern bloc”.

Federal President Theodor Heuss at documenta 1, 1955 © documenta archiv / Photo: Erich Müller

With “documenta. Politics and Art” the Deutsches Historisches Museum takes up the example of the famous exhibition in Kassel to shed light on the manifold interactions between politics and art in the society of the Federal Republic after 1945. Parallel to this, the exhibition “‘Divinely Gifted’. National Socialism’s favoured artists in the Federal Republic” (27.8.21 — 6.2.22) presents for the first time an examination of the post-war careers of so-called “divinely gifted” visual artists whom the Nazi authorities, from 1944 on, had deemed to be “indispensable” and were therefore exempt from front-line military service or other work for the war effort.

Raphael Gross, President of the Deutsches Historisches Museum: “With these exhibitions we want to bring to light a new perspective on the history of the Federal Republic in its international context. Both of them correct the notion of a radical aesthetic new beginning, which has often been attributed to the documenta and of which the early documenta framers made extensive use. There were, in fact, unbroken lines leading back to National Socialism. Works by murdered Jewish artists found no room in the early editions of the documenta. And in our exhibition on the previously almost unresearched ‘Divinely Gifted’, we are showing, conversely, the degree to which this group of visual artists who had been active in the Nazi cultural sector dominated the public space after 1945 and continue to dominate it to this day.”

Long Version: https://www.dhm.de/en/press/press-release/how-the-documenta-invented-the-zero-hour-in-art-after-1945/


Unveiling The Activities of Daily Living (ADL) Care Concept – Live life to the fullest with CERTAINTY

KUALA LUMPUR, MALAYSIA – Media OutReach – 1 March 2021 – CERTAINTY, a brand under Disposable Soft Goods (DSG) has recently unveiled the concept of Activities of Daily Living (ADL) to assist Malaysians in their purchasing behavior, primarily for its adult diaper selection. ADL is a commonly used term in the healthcare industry to refer to people’s daily life activities. ADL consists of 6 main activities which include eating, bathing, getting dressed, toileting, mobility and continence. With this new concept brought forth, DSG designed its CERTAINTY adult diapers that cater to the needs of the users, based on users’ mobility condition.

From left to right: Certainty DryPants for ADL0, Certainty SuperPants for ADL1, Certainty MaxPants for ADL2&3 and Certainty Tape diapers for ADL4&5.

Depending on the mobility condition of the user, the selection of the adult diapers is largely divided into ‘light to moderate’ or ‘moderate to heavy’ incontinence. Users who can walk independently or walk with walking aid, are generally having ‘light to moderate’ incontinence. Whereas users who need assistance or are bedridden, they normally have ‘moderate to heavy’ incontinence. Icon of the mobility condition and level of absorption are printed on the packaging to help consumers to choose the right type of adult diaper.

“We are very excited with this launch of the ADL care concept to Malaysian market. Applying the concept in our product design and development will certainly help users to select the right types of adult diapers to manage the issue of urinary incontinence.” said Daigo Fujiwara, Sales and Marketing Director.

In Malaysia, there are around 1.2 million people who are affected by some form of incontinence or inability to control any involuntary loss of urine. One in 10 women had regular incontinence problems while one in 20 men experienced it. There are generally two types of incontinence that mostly affect women, namely ‘stress incontinence’ and ‘urge incontinence’. Stress incontinence is caused due to coughing, laughing, sneezing, exercising or other movements that increase intra-abdominal pressure. Whereas, urge incontinence is involuntary and triggered by a random sound of running water or drinking small amounts of water.[1]


“Incontinence is not a disease. It is a symptom or a sign that some part of your body is not functioning properly. We believe it’s timely for us to introduce our range of adult diapers with the ADL care concept to cater to the increasing demand. The concept helps users to manage their incontinence issue as well as a guide for their caretakers to make the right choice in product selection.” added Daigo.

Based on the 6 (six) levels of the ADL care concept (from ADL 0 — ADL 5), Certainty guides users to better understand their user’s mobility conditions, thereby helping them to determine the right fit based on their urinary incontinence issue. With that, CERTAINTY adult diapers are now classified into 4 different types. The CERTAINTY DryPants and CERTAINTY SuperPants are catered to people who can walk or move around independently or with minimal walking aids respectively. Whereas, the CERTAINTY MaxPants are for people who require assistance, for example assisted by their caretaker and the CERTAINTY Tape is specially designed for bedridden patients.

With its tagline “For Everyday Confidence”, CERTAINTY believes its range of adult diapers are created based on the ADL care concept will allow both caretakers and people with urinary incontinence issues to live independently and confidently. For more information on the ADL care concept, please visit www.certainty.com.my or Facebook page at www.facebook.com/certaintymalaysia.”


[1] Urinary Incontinence

https://www.malaymail.com/news/malaysia/2013/08/11/1.2-million-malaysians-suffer-from-urinary-problems/507773

About Disposable Soft Goods

Disposable Soft Goods (DSG) started its operation in Malaysia with the setting up of Disposable Soft Goods (M) Sdn Bhd in October 1995, a company involved in the distribution of disposable baby and adult diapers. In July 1999, DSG set up its manufacturing plant, DSG (Malaysia) Sdn Bhd, in Glenmarie, Shah Alam. In 2013, DSG shifted to a fully integrated warehouse and manufacturing facilities located at Teluk Panglima Garang.

On 26 September 2018, Unicharm Corporation, a leading Japanese International Company that manufactures disposable hygienic products specializing in baby diapers, adult incontinence care, feminine hygiene, pet care and clean & fresh, has since acquired DSGT and its subsidiaries including DSG Malaysia. The management team of Unicharm and DSG is working collaboratively in accelerating the dramatic growth of DSG business.

From a start-up with a total workforce of only 57 employees, the company has grown and expanded its business operation with a workforce of more than 350 employees in 2020. DSG’s key brands are Certainty for adult diapers, PetPet and Fitti for baby diapers.

FWD Insurance and HKT team up to reward FWD MAX members with exclusive promotions

Members can experience telemedicine video consultation and unparalleled mobile 5G telecommunication services from CSL Mobile

 

HONG KONG SAR – Media OutReach – 1 March 2021 – FWD Insurance (“FWD”) is delighted to announce a new partnership with HKT (Stock Code: 6823) to offer FWD MAX members DrGo telemedicine video consultations and 5G telecommunication services from CSL Mobile.

Exclusive welcome offers and DrGo telemedicine video consultation rewards

From today until 30 June 2021, FWD MAX members are entitled to 2,000 MAX points (MAX points will be credited in the next calendar month), a HK$200 DrGo telemedicine consultation e-vouchers and a HK$50 Hung Fook Tong e-voucher upon account activation with the DrGo app.

Additionally, FWD MAX members can choose between redeeming a one-time DrGo consultation service with 8,750 MAX points or pay HK$330 plus 50 MAX points (valued at HK$368, which covers a single medical consultation with Union Medical Healthcare, up to three days of basic medication by general practitioners, and a one-time free medicine delivery service). For each completed consultation with DrGo app, MAX members will earn extra 500 MAX points. The e-voucher is applicable to these offerings.1

To register for the service, please visit https://drgohkt.page.link/download_app to download the DrGo app. For more information about DrGo service, please call +852 2380 2323 or visit www.drgo.com.hk.

5G service from CSL Mobile


From now until June 30, 2021, FWD MAX members subscribing to designated 1O1O or CSL 80GB 5G service plans are entitled to a free DrGo telemedicine consultation.2 In addition, 1O1O/csl data charges will be waived for FWD MAX members when using DrGo.

For details of pricing and service plans, please visit any 1O1O Center or csl store, or call 1O1O’s Product Hotline on +852 2988 1010, or csl’s Product Hotline on +852 2888 2123. Alternatively, you can WhatsApp one of csl’s online sales specialists on +852 52 123 123, or call one of 1O1O’s customer representatives on +852 5910 1010.

1. For DrGo Welcome Gift terms and conditions, please visit https://www.drgo.com.hk/terms-and-conditions/index.html.

2. Required to subscribe to a designated service plan. Terms & Conditions apply. Please contact shop staff for details.

About FWD Hong Kong & Macau

FWD Hong Kong & Macau is part of the FWD Group, the primary insurance business of investment group, Pacific Century Group. FWD Group spans Hong Kong SAR & Macau SAR, Thailand, Indonesia, the Philippines, Singapore, Vietnam, Japan and Malaysia, offering life and medical insurance, general insurance, employee benefits, Shariah and family takaful products across a number of its markets.

FWD Hong Kong has been assigned strong financial ratings by international agencies. It offers life and medical insurance, general insurance, employee benefits, and financial planning. FWD Macau provides a suite of life and medical insurance.

By creating fresh customer experiences with easy-to-understand products supported by digital technology, FWD aims to become a leading pan-Asian insurer that changes the way people feel about insurance.

For more information about FWD Hong Kong & Macau please visit www.fwd.com.hk and www.fwd.com.mo.

About FWD MAX


FWD MAX is an online-to-offline engagement platform aiming to encourage Hong Kong people to ignite their passions for life and pursue their aspirations. Every Hong Kong people, including FWD customers, can be a MAX member. Simply by sharing and participating in the platform’s diverse activities, users can earn MAX points to redeem life-enriching experiences and live life to the max. Please visit https://fwdmax.fwd.com.hk/#/.

About HKT


HKT (SEHK: 6823) HKT Hong Kong’s premier telecommunications service provider and a leading innovator. Its fixed-line, broadband, mobile communication and media entertainment services offer a unique quadruple-play experience. HKT meets the needs of the Hong Kong public and local and international businesses with a wide range of services including local telephony, local data and broadband, international telecommunications, mobile, media entertainment, enterprise solutions and other telecommunications businesses such as customer premises equipment sales, outsourcing, consulting and contact centers.

HKT is the first local mobile operator to launch a true 5G network with differentiated value-added services. Backed by its substantial holding of 5G spectrum across all bands and a robust and extensive fiber backhaul infrastructure, HKT is committed to providing comprehensive 5G network coverage across the city.

HKT delivers end-to-end integrated solutions employing emerging technologies such as 5G, cloud computing, Internet of Things (IoT) and artificial intelligence (AI) to accelerate the digital transformation of enterprises and contribute to Hong Kong’s development into a smart city.

Riding on its massive loyal customer base, HKT has also built a digital ecosystem integrating its loyalty program, e-commerce, travel, insurance, FinTech and HealthTech services. The ecosystem deepens HKT’s relationship with its customers thereby enhancing customer retention and engagement.

For more information, please visit www.hkt.com.

About DrGo


DrGo is a brand new end-to-end app-based platform connecting users with Hong Kong registered doctors who will provide medical consultation services and advice via video consultation on mobile device. Any prescribed medicine will be delivered to the user’s designated address. DrGo is the first HealthTech platform pioneered by HKT, offering convenient telemedicine services via on an end-to-end app-based platform developed and managed locally by HKT professionals. With HKT’s advanced technologies, the entire consultation journey including service registration, appointment booking, video consultation and payment will take place with encryption, aiming at protecting users’ privacy.

DrGo users in Hong Kong can get access to a one-stop medical consultation via their mobile devices. They can speak to a doctor from their home or workplace without the need to making a physical visit or queuing at a hospital or clinic. Remote consultation provides sense of ease and convenience, which is particularly important at a time when social distancing is critical during the current pandemic.

This press release is distributed by HKT and FWD Insurance.

HKT Limited is a company incorporated in the Cayman Islands with limited liability.

FWD Life Insurance Company (Bermuda) Limited is a company incorporated in Bermuda with limited liability.

Government of Laos Dissolves Ministry of Science and Technology

Ministry of Science and Technology

The government of Laos has dissolved the Ministry of Science and Technology, transferring its departments to various different ministries.

First Phase of Sithandone SEZ Development Project Underway

Khonephapheng SEZ

When completed, the first phase of the Sithandone Special Economic Zone (SEZ) is expected to be valued at some USD 600 million.

Fellows Creative Staff Singapore opened their Singapore office to help the creative content of all businesses stand out in the DX era by sourcing creators and digital talents

SINGAPORE – Media OutReach – 1 March 2021With everyone stuck at home during the pandemic, more people are exposed to many different creative contents without any doubt. Netflix is becoming popular and popular, the number of contents has been increasing inside YouTube, some people are purchasing twice more than usual via Lazada and Shopee, websites are crawled for searching a staycation place and Instagram or Twitter is checked every second. Creative content is everywhere more than ever.

Fellows Creative Staff Singapore Ptd. Ltd. Launched its office in Singapore in January 2020 to help businesses’ creative content stand out by sourcing creators and digital talents to all industries in the DX era. Fellows Creative Staff Singapore will eagerly contribute to all industries more flourish in Singapore and other ASEAN nations.

Would you believe your company has already had enough creative and digital talents?

Since 2003, Fellows Inc has spread out into 12 branches all over Japan. As of April 2020, more than 35.000 people registered and exceed 4,000 companies as their clients to be dedicated. Including from major TV stations, game developers to small and medium-sized animation productions, design offices, and digital service providers.

In Singapore, those people working in creative and digital fields also need to find more opportunities to stand out, meanwhile, almost all of enterprises are in need to break their old style of business and make them fit for a digital transformation under pandemic. That is what Fellows can help.

Junya Oishi, managing director of this creator’s agent, says “The word ‘creator’ indicates a wide range of professionals working in industries like web-contents, digital marketing, video production, console video & social network game, Japanese anime, product design, spatial & architectural design and we will cover all of them.”

Unique agent system called “Dual-Side Agent(DSA)”

Known as a “dual-side agent”, directly serves both creator and business owner in pursuit of ideal partnerships for both sides. In other words, a single DSA grasps the requirement of both parties clearly and reduces a wrong matching as much as possible. Fellows Creative Staff Singapore Pte. Ltd. affords a guaranteed permanent placement of a variety of talents and specialists in creative fields who are seeking employment. It also empowers to have project-based staffing by sourcing skilled and experienced free-lancers other than permanent placement.

How to use DSA

Under the Covid-19 pandemic, every business owner is looking for ways to survive. Thus, they may unwillingly retrench their precious employee or must accept a business reduction.

“However, there will never be a better chance than now to find new talents to let them join your team” Junya added.

As the Singapore Government encourages us to hire local citizens, Fellows Creative Staff Singapore Pte. Ltd. will support local jobseekers to find a new place to work as well. For both employers and job seekers who would like to use DSA, feel free to contact Junya Oishi at Fellows Creative Staff Singapore Pte. Ltd. (contact info at the bottom). Fees are not charged to employers until they found whom they want. Absolutely no charge for job seekers.

And for everyone dedicated to creative fields, Fellows Creative Staff Singapore is preparing various types of webinars which will give everyone a chance to learn new skills, improve technique and meet more people. * the Only webinar in Japanese is now available.

Fellows Creative Staff Singapore also plans to offer an “enterprise matching” service. For example, if a local company seeks to have a connection to an Anime production in Japan for investment or M&A, Fellows will help to find through its excellent network as a consultancy.

For more information about Fellows, please visit

・Fellows Creative Staff Singapore

https://www.fellow-s.com.sg/about-us-2/

・Fellows Inc

https://www.fellow-s.co.jp/

Novartis Piqray® – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval[1]

  • Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation
  • The approval was based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs. 5.7 months) in HR+/HER2- advanced breast cancer patients with PIK3CA mutation, compared to fulvestrant alone.
  • Approximately 30-40% of those with HR+/HER2- subtype have a PIK3CA mutation, which is associated with a poor prognosis. In Singapore, the incidence of point mutations in PIK3CA, are amongst the most frequently reported to date for any gene in breast cancer.

SINGAPORE – Media OutReach – 1 March 2021 – Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor, for the treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2-) negative, advanced breast cancer with a PIK3CA mutation in combination with fulvestrant after disease progression following an endocrine-based regimen.1

“Novartis has been researching the role of the PIK3CA mutation for more than 20 years and studying how to target this mutation in order to delay disease progression,” said Itsaraet Gosriwatana, Oncology General Manager, Novartis (Singapore). “The understanding of the PIK3CA status is crucial in equipping doctors to develop a better personalized treatment plan for patients. Today, we are pleased to be able to offer patients in Singapore with PIQRAY, an important new therapy for HR+/HER2- advanced breast cancer patients whose tumours have a PIK3CA mutation.”

HSA approval is based on results of the Phase III trial, SOLAR-1, that showed Piqray plus fulvestrant nearly doubled median progression-free survival (PFS) compared to fulvestrant alone in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation (median PFS 11.0 months vs 5.7 months; Hazard Ratio (HR)=0.65, 95% CI: 0.50-0.85; p<0.001).2 Piqray provided consistent PFS results across pre-specified subgroups, including among patients previously treated with a CDK4/6 inhibitor.2

The overall response rate (ORR), an indicator of the proportion of patients who experience at least a 30% reduction in overall tumor size (in patients with measurable disease), was more than doubled when Piqray was added to fulvestrant in patients with a PIK3CA mutation, (ORR = 35.7% vs 16.2% for fulvestrant alone, p=0.0002).2,3

Patients with HR+/HER2- advanced breast cancer should be selected for treatment with Piqray, based on the presence of a PIK3CA mutation in tumor tissue or plasma specimens, using a validated test. If a mutation is not detected in a plasma specimen, tumor tissue should be tested if available.1

“The PIK3CA gene is frequently mutated in HR+/HER2- breast cancer, affecting about 30% to 40% of people with that subtype 2. Advanced breast cancer patients with the PIK3CA mutations tend to have worse prognosis, developing resistance to standard treatment options more quickly.6,8,9,10,” said Associate Prof Yap Yoon Sim, Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore.

In Singapore, a total of 9,634 new cases of breast cancer cases were diagnosed between 2011 — 2015, accounting for nearly 1 in 3 incident cancers in females and making it the most common cancer diagnosis among women. Of which, 1 in 10 women diagnosed with breast cancer are of advanced stages.7 The incidence of point mutations in PIK3CA, are amongst the most frequently reported to date for any gene in breast cancer in Singapore.4

Approximately 30-40% of those with HR+/HER2- subtype of breast cancer have a PIK3CA mutation2. PIK3CA mutations are associated with tumor growth, resistance to endocrine treatment and a poor overall prognosis.6,8,9,10 Piqray targets the effect of PIK3CA mutations and may help overcome endocrine resistance in HR+ advanced breast cancer.

PIQRAY is the first drug of its kind approved for treatment of postmenopausal women, and men, with hormone receptor positive, HER2- negative, advanced breast cancer with a PIK3CA mutation in Singapore, the European Union, and the United States.

About Piqray® (alpelisib)

Piqray is a kinase inhibitor approved in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+/HER2-, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after endocrine-based regimen.1

Approximately 30-40% of HR+ advanced breast cancer patients have a mutation that may activate the PI3K-alpha isoform, called PIK3CA mutations.2 These mutations are associated with resistance to endocrine therapy, disease progression and a poor prognosis.6,8,9,10 Piqray works by inhibiting the PI3K pathway, predominantly the PI3K-alpha isoform, to address the effect of PIK3CA mutations.

About SOLAR-1

SOLAR-1 is a global, Phase III randomized, double-blind, placebo-controlled trial studying Piqray in combination with fulvestrant for postmenopausal women, and men, with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer that progressed on or following aromatase inhibitor treatment with or without a CDK4/6 inhibitor 2,3. SOLAR-1 is the pivotal Phase III trial that supported this approval.

The trial randomized 572 patients. Patients were allocated based on central tumor tissue assessment to either a PIK3CA-mutated cohort (n=341) or a PIK3CA non-mutated cohort (n=231). Within each cohort, patients were randomized in a 1:1 ratio to receive continuous oral treatment with Piqray (300 mg once daily) plus fulvestrant (500 mg every 28 days + Cycle 1 Day 15) or placebo plus fulvestrant. Stratification was based on visceral metastases and prior CDK4/6 inhibitor treatment2,3. Patients and investigators are blinded to PIK3CA mutation status and treatment.

The primary endpoint is local investigator assessed PFS using RECIST 1.1 for patients with a PIK3CA mutation. The key secondary endpoint is overall survival, and additional secondary endpoints include, but are not limited to, overall response rate, clinical benefit rate, health-related quality of life, efficacy in PIK3CA non-mutated cohort, safety and tolerability2. SOLAR-1 is ongoing to assess overall survival and other secondary endpoints.

About Novartis in Advanced Breast Cancer

For more than 30 years, Novartis has been tackling breast cancer with superior science, great collaboration and a passion for transforming patient care. With one of the most diverse breast cancer pipelines and one of the largest numbers of breast cancer compounds in development, Novartis leads the industry in discovery of new therapies and combinations, especially in HR+ advanced breast cancer, the most common form of the disease.

Indication 1

Piqray is an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor indicated for the treatment of postmenopausal women, and men, with hormone receptor positive, HER2- negative, advanced breast cancer with a PIK3CA mutation in combination with fulvestrant after disease progression following an endocrine-based regimen.

Important Safety Information 1

Treatment with Piqray should be initiated by a physician experienced in the use of anticancer therapies.

Piqray is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients. PIQRAY may cause serious side effects. PIQRAY can cause hypersensitivity (including anaphylactic reaction), manifested by symptoms including, but not limited to, dyspnea, flushing, rash, fever or tachycardia.

The most common adverse drug reactions in Piqray plus fulvestrant treated patients were hyperglycaemia, diarrhea, rash, nausea, fatigue and asthenia, decreased appetite, stomatitis, vomiting and weight decreased.

Patients should tell their health care provider all of the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. PIQRAY and other medicines may affect each other causing side effects.

For more information, please see full Prescribing Information for Piqray, available at

https://www.novartis.com.sg/product-list/PIQRAY

*HSA approval for PIQRAY on 25th March 2020

References

  1. Piqray (alpelisib) Singapore Prescribing Information. Novartis Singapore; Jan 2020.
  2. André F, Ciruelos E, Rubovszky G. Alpelisib for PIK3CA-Mutated, Hormone-Receptor-Positive Advanced Breast Cancer. N Eng J Med 2019.
  3. Juric D, Ciruelos EM, Rubovszky G et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Phase 3 SOLAR-1 trial results. Presented at the San Antonio Breast Cancer Symposium (SABCS) (Abstract #GS3-08) on December 6, 2018.
  4. Liang, X., Lau, Q., Salto-Tellez, M., Putti, T., Loh, M. and Sukumar, S., 2006. Mutational hotspot in Exon 20 of PIK3CA in breast cancer among singapore chinese. Cancer Biology & Therapy , 5(5), pp.544-548.
  5. Moynahan ME, Chen D, He W, et al. Br J Cancer. 2017;116(6):726-730002E
  6. Miller TW, Rexer BN, Garrett JT, et al. Mutations in the Phosphatidylinositol 3-Kinase Pathway: Role in Tumor Progression and Therapeutic Implications in Breast Cancer. Breast Cancer Res. 2011.
  7. National Registry of Diseases Office (NRDO).Singapore Cancer Registry Annual Registry Report 2015. Jun 2017
  8. Sobhani N, Roviello G, Corona SP et al. The prognostic value of PI3K mutational status in breast cancer: a meta-analysis. J Cell Biochem. 2018;119(6):4287-4292.
  9. Sabine V, Crozier C, Brookes C, et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. Journal of Clinical Oncology. 2014;32:2951-2958.
  10. Saal LH, Johansson P, Holm K. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. PNAS. 2007;104(18):7564-7569.

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Global

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis

For Novartis multimedia content, please visit www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com